/Tonghua Golden Horse: Third Quarter Report of 2025

NEWS

Tonghua Golden Horse: Third Quarter Report of 2025

Shenzhen Stock Exchange

2025/10/27

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Securities code: 000766 Securities abbreviation: Tonghua Jinma Announcement number: 2025-37

Tonghua Jinma Pharmaceutical Group Co., Ltd.

2025 Third Quarter Report

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions. Important content reminder:

The board of directors, directors and senior managers guarantee that the quarterly report is true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.
The person in charge of the company, the person in charge of accounting work and the person in charge of the accounting department (accounting supervisor) declare that they guarantee the authenticity, accuracy and completeness of the financial information in the quarterly report.
Whether the third quarter financial accounting report has been audited

□Yes No

1. Main financial data

(1) Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

□Yes No

This reporting period compared with the same period last year. From the beginning to the end of the reporting period. Compared with the same period last year. From the beginning to the end of the reporting period.

Increase/decrease Increase/decrease in operating income during the same period of the year (yuan) 242,267,320.96 -24.15% 892,251,129.40 -7.88% attributed to shareholders of listed companies

8,159,473.51 -28.77% 24,963,468.01 4.35% net profit (yuan)

Attributable to shareholders of listed companies

Net profit after deducting non-recurring gains and losses 4,932,132.89 -50.61% 19,339,397.59 18.01% (yuan)

Cash generated from operating activities

— — 70,813,021.95 -36.44% Net flow (yuan)

Basic earnings per share (yuan/

0.0084 -29.41% 0.0258 4.03% shares)

Diluted earnings per share (yuan/

0.0084 -29.41% 0.0258 4.03% shares)

weighted average net asset income

0.36% -0.13% 1.10% 0.07% rate

The end of the reporting period. The end of the previous year. The increase or decrease at the end of the reporting period compared with the end of the previous year.

Total assets (yuan) 4,527,625,159.18 4,483,618,602.64 0.98% belongs to shareholders of listed companies

2,301,207,463.18 2,255,397,745.17 2.03% owner’s equity (yuan)

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

(2) Non-recurring profit and loss items and amounts

Applicable □Not applicable

Unit: Yuan

Item Amount for this reporting period Amount from the beginning of the reporting period to the end of the reporting period Explanation of gains and losses from disposal of non-current assets (including

Including the write-off part of the asset impairment provision that has been made -48,350.19)

Government subsidies included in current profits and losses

(Close to the normal business operations of the company

Relevant, in line with national policies and regulations,

3,864,725.56 6,761,660.46 Enjoyed according to determined standards, to the public

government that has a lasting impact on the company's profits and losses

Except for subsidies)

Except related to the company's normal business operations

In addition to effective hedging business, non-

Financial enterprises hold financial assets and gold

7,586.80 -18,675.20 Changes in fair value of financial liabilities

Profit and loss and disposal of financial assets and funds

Profit and loss arising from financial liabilities

Entrusting others to invest or manage assets

2,078.29 11,859.12Profit and loss

Gains and losses from debt restructuring -119,155.10 Other businesses other than the above items

-261,113.15 -556,685.95External income and expenses

Less: Income tax impact 385,936.88 406,582.72 Total 3,227,340.62 5,624,070.42 --Details of other profit and loss items that meet the definition of non-recurring gains and losses:

□Applicable Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

□Applicable Not applicable

The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.

(3) Changes in major accounting data and financial indicators and their reasons

Applicable □Not applicable

Accounting account Ending balance (yuan) Beginning balance (yuan) Change range Reason for change Accounts receivable Bank acceptances held during the period 47,276,809.26 26,715,894.78 76.96%

Capital due to increase in bills of exchange. Increase in short-term borrowings from bank loans in this period 259,723,459.70 194,748,486.10 33.36%

To. Due within one year

Non-current liabilities repaid to long-term borrowing institutions in the current period 1,758,993.75 1,604,722,682.55 -99.89%

To.

debt

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Accounting account Amount incurred in the current period (yuan) Amount incurred in the previous period (yuan) Range of change Reason for change

Value-added tax increase and surcharges paid in the current period 10,820,968.48 6,837,065.04 58.27%

Caused by growth.

The company’s investment income in this period 883,866.55 3,275,211.48 -73.01%

due to reduced profits.

Credit impairment loss Provision for bad debts in the current period is -2,450,492.03 -5,558,214.68 55.91%

The loss was due to the decrease in the same period last year. business activity assets

Cash flow from deposit received in this period compared to the previous period 70,813,021.95 111,407,499.68 -36.44%

Due to the decrease in the same period last year. Net amount

financing activity assets

Cash flow from loan repayments in this period compared with the previous year -18,038,034.00 15,649,769.05 -215.26%

due to growth over the same period.

Net amount

2. Shareholder information

(1) The total number of common shareholders, the number of preferred shareholders whose voting rights have been restored, and the shareholding status of the top ten shareholders

Unit: Share Total number of common shareholders at the end of the reporting period 38,232 Total number of preference shareholders whose voting rights were restored at the end of the reporting period (if any) 0 Shareholding status of the top 10 shareholders (excluding shares lent through refinancing)

Holding of sales restrictions Pledge, mark or freeze Name of shareholder Nature of shareholder Shareholding ratio Number of shares held

Number of shares in the case Share status Quantity Yu Lanjun Domestic natural person 19.66% 190,000,000 0 Pledge 150,000,000 Shanghai Mukai Trading Domestic non-state-owned law

4.86% 46,992,000 0 Not applicable 0 Co., Ltd. Person

Sun Changhao Domestic natural person 4.61% 44,579,900 0 Pledge 20,000,000 Li Jia Domestic natural person 4.51% 43,599,900 0 Pledge 32,700,000 Tang Xiaoni Domestic natural person 2.07% 20,000,000 0 Pledge 20,000,000 Tonghua Yongxin Investment

Limited liability company State-owned legal person 2.07% 20,000,000 0 Pledge 10,000,000

Bank of Shanghai Shares

Ltd.-Silver

Huazhong Innovative Drugs

Others 0.95% 9,192,991 0 Not applicable 0 Industrial transaction type

open index securities

investment fund

China Merchants Bank

Ltd - South

Fang Zhongzheng 1000

Others 0.91% 8,841,600 0 Not applicable 0 Trading open

Index Securities Investment

fund

Hong Kong Securities Clearing Company

Overseas legal person 0.75% 7,267,136 0 Not applicable 0 Limited company

China Merchants Bank

Co., Ltd. - Hua

Xia Zhongzheng 1000

Others 0.54% 5,253,100 0 Not applicable 0 Trading open-ended

Index Securities Investment

fund

Shareholdings of the top 10 shareholders without sales restrictions (excluding shares lent through refinancing and shares locked by executives)

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Type and quantity of shares

Name of shareholder Number of shares without selling restrictions held

Type of shares Quantity Yu Lan Jun 190,000,000 RMB ordinary shares 190,000,000 Shanghai Mukai Trading Co., Ltd. 46,992,000 RMB ordinary shares 46,992,000 Sun Changhao 44,579,900 RMB ordinary shares 44,579,900 Li Jia 43,599,900 RMB ordinary shares 43,599,900 Tang Xiaoni 20,000,000 RMB ordinary shares 20,000,000 Tonghua Yongxin Investment Co., Ltd. 20,000,000 RMB ordinary shares 20,000,000 Bank of Shanghai Co., Ltd.-Yinhua Zhong

Zhengxin Pharmaceutical Industry Trading Open Index 9,192,991 RMB ordinary shares 9,192,991 Securities investment funds

China Merchants Bank Co., Ltd.-South China

Securities 1000 trading open-end index securities 8,841,600 RMB ordinary shares 8,841,600 investment funds

Hong Kong Securities Clearing Company Limited 7,267,136 RMB ordinary shares 7,267,136 China Merchants Bank Co., Ltd.-China AMC

Securities 1000 trading open-end index securities 5,253,100 RMB ordinary shares 5,253,100 investment funds

There is no related relationship between the largest shareholder among the above ten shareholders and other shareholders, and there is no

They are persons acting in concert as stipulated in the "Measures for the Administration of Acquisitions of Listed Companies". Unknown explanations of related relationships or concerted actions among the above-mentioned shareholders of other shares

Whether Dong is a person acting in concert as stipulated in the "Measures for the Administration of Acquisitions of Listed Companies", and whether there are related relationships among other shareholders is unknown.

The credit securities account of shareholder Shanghai Mukai Trading Co., Ltd. holds 39,900,000 shares of the company, and the ordinary account holds 7,092,000 shares of the company, for a total of 46,992,000 shares of the company. Shareholder Sun Changhao holds company stocks in his credit securities account

24,570,000 shares, the general account holds 20,009,900 shares of the company, and a total of 44,579,900 shares of the company are held by the top 10 shareholders (if any). The shareholder Li Jia's credit securities account holds 10,890,000 shares of the company, and the ordinary account holds 32,709,900 shares of the company, for a total of 43,599,900 shares of the company. The shareholder Tonghua Yongxin Investment Co., Ltd. holds 10,000,000 shares of the company's stock in its credit securities account, and its ordinary account holds the company's shares.

holds 10,000,000 shares of the company's stock, and holds a total of 20,000,000 shares of the company's stock.

The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable Not applicable

(2) Total number of preferred shareholders of the company and shareholding status of the top 10 preferred shareholders

□Applicable Not applicable

3. Other important matters

□Applicable Not applicable

4. Quarterly Financial Statements

(1) Financial statements

Consolidated balance sheet

Prepared by: Tonghua Jinma Pharmaceutical Group Co., Ltd.

September 30, 2025

Unit: Yuan

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Item Ending balance Beginning balance

Current assets:

Monetary funds 322,275,651.85 274,177,490.80 Settlement reserves

Loan funds

Trading financial assets 1,077,887.20 1,088,562.40 Derivative financial assets

Notes receivable

Accounts receivable 493,623,944.11 499,551,966.08 Accounts receivable financing 47,276,809.26 26,715,894.78 Prepayments 6,136,365.47 10,568,328.57 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 15,748,820.43 15,330,106.14 Including: interest receivable

Dividends receivable

Buy financial assets under resale agreements

Inventory 381,173,710.35 382,193,097.01

Among them: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 339,480.05 338,786.97 Total current assets 1,267,652,668.72 1,209,964,232.75 Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

Long-term equity investment 55,702,979.38 54,711,816.85 Other equity instrument investment 1,774,591,839.87 1,774,591,839.87 Other non-current financial assets 18,767,437.20 18,767,437.20 Investment real estate

Fixed assets 671,179,840.20 696,380,682.16 Construction in progress 298,486,971.23 272,264,111.72 Productive biological assets 17,780,064.82 17,301,782.46 Oil and gas assets

Right-of-use assets 2,848,515.68 3,892,326.87 Intangible assets 174,602,080.08 184,963,415.10

Among them: data resources

Development expenditure 207,337,665.21 189,382,161.53

Among them: data resources

Goodwill 1,900,200.00 1,900,200.00 Long-term deferred expenses 533,398.93 834,755.32 Deferred income tax assets 27,834,399.72 31,728,538.77 Other non-current assets 8,407,098.14 26,935,302.04 Total non-current assets 3,259,972,490.46 3,273,654,369.89 Total assets 4,527,625,159.18 4,483,618,602.64 Current liabilities:

Short-term borrowings 259,723,459.70 194,748,486.10 Borrowings from the central bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Notes payable 3,586,554.25 157,500.00 Accounts payable 144,351,065.74 182,157,403.80 Advance payments

Contract liabilities 13,748,530.56 14,655,484.00 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Agent underwriting securities funds

Employee benefits payable 14,631,667.09 18,842,937.65 Taxes payable 15,677,853.03 20,360,339.39 Other payables 109,844,192.41 119,754,915.73 Including: interest payable

Dividends payable 3,591,660.93 3,591,660.93 Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 1,758,993.75 1,604,722,682.55 Other current liabilities 1,089,219.04 1,466,559.02 Total current liabilities 564,411,535.57 2,156,866,308.24 Non-current liabilities:

insurance contract reserves

Long-term borrowings 1,593,576,666.67

bonds payable

Among them: preferred shares

perpetual bond

Lease liabilities 3,125,579.11 2,828,269.82 Long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 63,155,436.05 65,531,781.71 Deferred income tax liabilities 2,115,326.91 2,989,321.10 Other non-current liabilities

Total non-current liabilities 1,661,973,008.74 71,349,372.63 Total liabilities 2,226,384,544.31 2,228,215,680.87 Owners’ equity:

Share capital 966,494,707.00 966,494,707.00 Other equity instruments

Among them: preferred shares

perpetual bond

Capital reserve 3,579,299,174.29 3,579,299,174.29 Less: treasury shares

Other comprehensive income -97,856,250.00 -118,702,500.00 Special reserves

Surplus reserve 108,648,108.59 108,648,108.59 General risk reserve

Undistributed profits -2,255,378,276.70 -2,280,341,744.71 Total owners’ equity attributable to the parent company 2,301,207,463.18 2,255,397,745.17 Minority shareholders’ equity 33,151.69 5,176.60 Total owners’ equity 2,301,240,614.87 2,255,402,921.77 Total liabilities and owners’ equity 4,527,625,159.18 4,483,618,602.64 Legal representative: Zhang Yufu Person in charge of accounting work: Yu Jun Person in charge of the accounting department: Geng Lan

Consolidated income statement from the beginning of the year to the end of the reporting period

Unit: Yuan

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Item Amount for the current period Amount for the previous period

Total operating income 892,251,129.40 968,589,176.59 Including: operating income 892,251,129.40 968,589,176.59 Interest income

Premiums earned

Fee and commission income

Total operating costs 862,582,077.49 944,525,450.04 Including: operating costs 244,696,332.11 238,383,760.40 Interest expenses

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 10,820,968.48 6,837,065.04 Sales expenses 434,722,717.36 525,253,917.92 Management expenses 84,219,082.83 88,191,843.06 Research and development expenses 27,991,552.63 28,499,623.60 Financial expenses 60,131,424.08 57,359,240.02 Including: interest expenses 60,962,450.32 61,879,914.99

Interest income 1,328,685.90 2,145,876.43 plus: other income 7,603,416.08 7,256,584.12 Investment income (losses are filled in with "-"

883,866.55 3,275,211.48 columns)

Of which: for associates and joint ventures

corporate investment income

Measured at amortized cost

Income from derecognition of financial assets

Exchange gains (losses are filled in with "-"

column)

Net exposure hedging gain (loss calculated as

Fill in the column with "-" sign)

Gains from changes in fair value (losses calculated as

-18,675.20 11,672.00 (Fill in “-”)

Credit impairment losses (losses are marked with "-"

-2,450,492.03 -5,558,214.68 fill in the column)

Asset impairment losses (losses are marked with "-"

-493,869.83 -2,767,328.53 fill in the column)

Asset disposal income (losses are marked with "-"

-48,350.19 -189,140.51 fill in the column)

3. Operating profit (loss is filled in with "-"

35,144,947.29 26,092,510.43 columns)

Add: Non-operating income 417,791.13 1,159,291.44 Less: Non-operating expenses 974,477.08 1,455,695.48

4. Total profit (total loss is marked with "-"

34,588,261.34 25,796,106.39 fill in the column)

Less: Income tax expenses 9,596,818.24 1,931,449.65

5. Net profit (net loss is filled in with "-"

24,991,443.10 23,864,656.74 columns)

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

(1) Classification by business continuity

Net profit from continuing operations (net loss divided by

24,991,443.10 23,864,656.74 (Fill in “-”)

Net profit from discontinued operations (net loss equal to

Fill in the column with "-" sign)

(2) Classification according to ownership ownership

Net profit attributable to shareholders of the parent company

24,963,468.01 23,923,749.83 (Net loss is listed with "-")

Profit and loss of minority shareholders (net loss is represented by “-”

No. 27,975.09-59,093.09 (please fill in the list)

Net after-tax amount of other comprehensive income 20,846,250.00 Other comprehensive income attributable to the owners of the parent company

Net amount after tax of 20,846,250.00

(1) Others that cannot be reclassified into profit or loss

Comprehensive income 20,846,250.00

Remeasure changes in defined benefit plans

Others that cannot be transferred to profit or loss under the equity method

Comprehensive income

Fair value of other equity instrument investments

change

Fair value of the company’s own credit risk

change

Others 20,846,250.00

(2) Other comprehensive items that will be reclassified into profit or loss

combined income

Other comprehensive items that can be transferred to profits and losses under the equity method

combined income

Changes in fair value of other debt investments
Financial assets are reclassified into other comprehensive

Amount of combined income

Credit impairment provisions for other debt investments
Cash flow hedging reserve
Translation differences of foreign currency financial statements

7.Others

Other comprehensive income attributable to minority shareholders

net of tax

Total comprehensive income 45,837,693.10 23,864,656.74

(1) Comprehensive assets attributable to owners of the parent company

45,809,718.01 23,923,749.83Total income

(2) Comprehensive income attributable to minority shareholders

27,975.09 -59,093.09 total

8. Earnings per share:

(1) Basic earnings per share 0.0258 0.0248

(2) Diluted earnings per share 0.0258 0.0248 If a business merger under the same control occurs in this period, the net profit realized by the merged party before the merger is: 0.00 yuan, and the net profit realized by the merged party in the previous period is: 0.00 yuan. Legal representative: Zhang Yufu Person in charge of accounting work: Yu Jun Person in charge of accounting department: Geng Lan

Consolidated cash flow statement from the beginning of the year to the end of the reporting period

Unit: Yuan Item Amount of the current period Amount of the previous period

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 940,090,237.33 961,938,084.01 Net increase in customer deposits and deposits from banks

Net increase in borrowing from the central bank

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

tax refund received

Other cash received related to operating activities 19,421,767.54 32,546,136.28 Subtotal of cash inflows from operating activities 959,512,004.87 994,484,220.29 Cash paid for purchasing goods and receiving services 145,851,178.25 183,218,888.33

Net increase in loans and advances to customers

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 114,420,512.47 106,744,229.59 Various taxes and fees paid 123,301,848.70 69,907,379.24 Cash paid for other operating activities 505,125,443.50 523,206,223.45 Subtotal cash outflow from operating activities 888,698,982.92 883,076,720.61 Net cash flow generated from operating activities 70,813,021.95 111,407,499.68

2. Cash flow generated from investing activities:

Recover cash received on investment

Cash received from investment income 3,206.17

Disposal of fixed assets, intangible assets and other long-term

14,000.00 Net cash amount recovered from period 45,000.00 assets

Received from disposal of subsidiaries and other business units

net cash

Other cash received related to investing activities 27,403,466.89 2,848,923.34 Subtotal of cash inflows from investing activities 27,420,673.06 2,893,923.34 Purchase and construction of fixed assets, intangible assets and other long-term assets

32,611,451.88 26,192,583.07 Cash paid for assets

Cash paid for investments

Net increase in mortgage loans

Obtain payment from subsidiaries and other business units

net cash

Payment of other cash related to investing activities 2,878,340.28 2,848,511.95 Subtotal cash outflow from investing activities 35,489,792.16 29,041,095.02 Net cash flow generated from investing activities -8,069,119.10 -26,147,171.68

3. Cash flow generated from financing activities:

Absorbing cash received from investments

Among them: subsidiaries absorb investment from minority shareholders

cash received

Cash received from borrowings 1,840,050,000.00 234,500,000.00 Cash received from other financing activities 7,570,003.26 Subtotal of cash inflows from financing activities 1,840,050,000.00 242,070,003.26 Cash paid to repay debts 1,797,050,000.00 131,000,000.00 Distribution of dividends, profits or payment of interest

61,038,034.00 63,822,507.33 cash

Including: Payments made by subsidiaries to minority shareholders

dividends, profits

Tonghua Jinma Pharmaceutical Group Co., Ltd. 2025 Third Quarter Report

Payment of other cash related to financing activities 31,597,726.88 Subtotal of cash outflows from financing activities 1,858,088,034.00 226,420,234.21 Net cash flow generated from financing activities -18,038,034.00 15,649,769.05

4. The impact of exchange rate changes on cash and cash equivalents

influence

Net increase in cash and cash equivalents 44,705,868.85 100,910,097.05

Add: Balance of cash and cash equivalents at the beginning of the period 273,983,228.75 167,253,984.78

Balance of cash and cash equivalents at the end of the period 318,689,097.60 268,164,081.83

(2) Adjustment of relevant items in the financial statements at the beginning of the year when the new accounting standards are first implemented starting from 2025